首页> 外文会议>Conference on photodynamic therapy of cancer >Preliminary clinical studies of PDT with meso-tetrahydroxyphenyl chlorin (m-THPC) as a photosensitizing agent for the treatment of early pharyngeal esophageal and bronchial carcinomas
【24h】

Preliminary clinical studies of PDT with meso-tetrahydroxyphenyl chlorin (m-THPC) as a photosensitizing agent for the treatment of early pharyngeal esophageal and bronchial carcinomas

机译:PDT与中硫代苯基氯氯(M-THPC)作为治疗早期咽部食管和支气管癌的光敏剂的初步临床研究

获取原文

摘要

A new photosensitizer (PS), meso-tetrahydroxyphenyl-chlorin(m-THPC), has been clinically evaluated for photodynamic therapy (PDT) of early squamous cell carcinomas located in the upper aerodigestive tract, the oesophagus and the tracheobronchial tree. The injected doses ranged between 0.1 - 0.3 mg/kg m-THPC and the wavelength of the excitation light was either at 514 nm or 652 nm. The evaluation of the m-THPC induced phototoxicity was carried out on healthy mucosae of the bronchi, the oral cavity and the skin, using various `frontal' light distributors. Skin photosensitization tests were performed with a filtered Xenon white light source which simulates the solar emission spectrum at noon on a clear summer day at sea level at our latitude. At the present time, we are still searching for conditions where effective PDT with m-THPC of early carcinomas of the upper aerodigestive tract, the oesophagus and the tracheobronchial tree would show a real selectivity, i.e., destruction of the neoplastic tissue without necrosis of the surrounding normal tissue.
机译:一种新的光敏剂(PS),内消旋 - tetrahydroxyphenyl二氢卟酚(M-THPC),已在临床上评价位于上部呼吸消化道,食道和气管支气管树早期鳞状细胞癌的光动力疗法(PDT)。注入的剂量为0.1之间 - 0.3毫克/公斤米-THPC和激发光的波长为无论是在514纳米或652纳米。第m THPC诱发光毒性的评价是对支气管,口腔和皮肤的健康粘膜进行,使用各种`正面”光分布器。皮肤光敏试验与中午模拟在海平面一个晴朗的夏日,在我们的纬度太阳发射光谱滤波氙白色光源进行。目前,我们仍在寻找条件,其中与上呼吸消化道早期癌的M-THPC有效PDT,食道和气管支气管树将显示一个真正的选择性,即肿瘤组织的破坏没有坏死周围的正常组织。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号